CIMETIDINE by Novartis is clinical pharmacology cimetidine competitively inhibits the action of histamine at the histamine h 2 receptors of the parietal cells and thus is a histamine h 2 -receptor antagonist. First approved in 1995.
Drug data last refreshed 22h ago
CLINICAL PHARMACOLOGY Cimetidine competitively inhibits the action of histamine at the histamine H 2 receptors of the parietal cells and thus is a histamine H 2 -receptor antagonist. Cimetidine is not an anticholinergic agent. Studies have shown that cimetidine inhibits both daytime and nocturnal…
Worked on CIMETIDINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Cimetidine on the PK of Imeglimin
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
Drug-drug Interaction Study of CHF5993 With Cimetidine
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX